tiprankstipranks
Advertisement
Advertisement

AMLX Stock Latest News

Amylyx to present data from first-in-human, dose-ranging Phase 1 Lumina trial
The FlyAmylyx to present data from first-in-human, dose-ranging Phase 1 Lumina trial
1d ago
AMLX
Amylyx Shareholders Approve Directors, Auditor and Executive Pay
PremiumCompany Announcements
Amylyx Shareholders Approve Directors, Auditor and Executive Pay
20d ago
8K
AMLX
Amylyx announces publication of Phase 2 open-label HELIOS trial data
PremiumThe Fly
Amylyx announces publication of Phase 2 open-label HELIOS trial data
1M ago
AMLX
Amylyx Pharmaceuticals Charts Path to 2026 Trial Data
PremiumCompany Announcements
Amylyx Pharmaceuticals Charts Path to 2026 Trial Data
2M ago
AMLX
Buy Rating Reiterated on Amylyx as Avexitide Progress and Cash Runway Support Upside vs. Unchanged $24 Price Target
PremiumRatings
Buy Rating Reiterated on Amylyx as Avexitide Progress and Cash Runway Support Upside vs. Unchanged $24 Price Target
2M ago
AMLX
Amylyx reports Q1 EPS (37c), consensus (34c)
PremiumThe FlyAmylyx reports Q1 EPS (37c), consensus (34c)
2M ago
AMLX
Amylyx sees cash runway into 2028
Premium
The Fly
Amylyx sees cash runway into 2028
2M ago
AMLX
Amylyx announces launch of U.S. EAP for adults with PBH
Premium
The Fly
Amylyx announces launch of U.S. EAP for adults with PBH
2M ago
AMLX
Amylyx’s ORION Trial in Progressive Supranuclear Palsy Reaches Completion: What Investors Should Watch
PremiumCompany Announcements
Amylyx’s ORION Trial in Progressive Supranuclear Palsy Reaches Completion: What Investors Should Watch
2M ago
AMLX
Amylyx price target raised to $21 from $19 at Mizuho
PremiumThe Fly
Amylyx price target raised to $21 from $19 at Mizuho
2M ago
AMLX
Buy Rating on Amylyx: De-Risked Avexitide Phase III Study and Significant PBH Market Opportunity Support 2027 Launch Potential
PremiumRatings
Buy Rating on Amylyx: De-Risked Avexitide Phase III Study and Significant PBH Market Opportunity Support 2027 Launch Potential
3M ago
AMLX
Amylyx Highlights Pipeline Progress in Updated Corporate Presentation
PremiumCompany Announcements
Amylyx Highlights Pipeline Progress in Updated Corporate Presentation
3M ago
8K
AMLX
Amylyx completes enrollment in Phase 3 Lucidity trial of avexitide
PremiumThe FlyAmylyx completes enrollment in Phase 3 Lucidity trial of avexitide
3M ago
AMLX
Amylyx price target raised to $30 from $25 at Guggenheim
Premium
The Fly
Amylyx price target raised to $30 from $25 at Guggenheim
3M ago
AMLX
Buy Rating on Amylyx Pharmaceuticals Driven by Avexitide’s Commercial Potential and De-Risked Phase III PBH Program
Premium
Ratings
Buy Rating on Amylyx Pharmaceuticals Driven by Avexitide’s Commercial Potential and De-Risked Phase III PBH Program
3M ago
AMLX
Amylyx Pharmaceuticals Maps High-Stakes Path to 2027
PremiumCompany Announcements
Amylyx Pharmaceuticals Maps High-Stakes Path to 2027
4M ago
AMLX
Amylyx price target raised to $34 from $28 at H.C. Wainwright
PremiumThe Fly
Amylyx price target raised to $34 from $28 at H.C. Wainwright
4M ago
AMLX
Amylyx Pharmaceuticals: Solid Balance Sheet, Advancing Pipeline, and Attractive Risk‑Reward Support Buy Rating
PremiumRatings
Amylyx Pharmaceuticals: Solid Balance Sheet, Advancing Pipeline, and Attractive Risk‑Reward Support Buy Rating
4M ago
AMLX
Amylyx files automatic mixed securities shelf
PremiumThe Fly
Amylyx files automatic mixed securities shelf
4M ago
AMLX
Amylyx reports Q4 EPS (30c), consensus (34c)
PremiumThe FlyAmylyx reports Q4 EPS (30c), consensus (34c)
4M ago
AMLX
Amylyx initiated with a Buy at Stifel
Premium
The Fly
Amylyx initiated with a Buy at Stifel
4M ago
AMLX
Is AMLX a Buy, Before Earnings?
Premium
Pre-Earnings
Is AMLX a Buy, Before Earnings?
4M ago
AMLX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >